{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-038044","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.156693+00:00","generated_at":"2026-06-04T05:58:43.815633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Assembly Bio reports FY 2023 net loss of $61.2M; cash of $130.2M; outlines 2024 milestones","bullets":["Cash, equivalents and marketable securities $130.2M as of Dec 31, 2023, up from $91.6M at end of 2022; funded into H2 2025.","Revenue from collaborations $7.2M in FY 2023 (vs $0 in 2022), primarily from Gilead partnership.","R&D expenses $48.9M (down from $70.0M); net loss $61.2M ($13.38/share) vs $93.1M ($23.08) in 2022.","Phase 1a interim data for HSV drug ABI-5366 expected Q3 2024; Phase 1b data for HBV drug ABI-4334 by end of 2024.","Entered long-term partnership with Gilead and appointed Anuj Gaggar as CMO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-038044","json":"https://secwatch.observer/filing/0000950170-24-038044.json","markdown":"https://secwatch.observer/filing/0000950170-24-038044.md","text":"https://secwatch.observer/filing/0000950170-24-038044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024038044/0000950170-24-038044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024038044/asmb-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:58:43.815633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02011700845e7ed4406f98156996118ac41a7ef2","claim":"ASSEMBLY BIOSCIENCES, INC. reported the quarter and year ended December 31, 2023 results: revenue $7.2 million, net income $61.2 million, EPS $13.38 per basic and diluted share.","evidence_excerpt":"as of the year ended December 31, 2022. The company’s cash position is projected to fund operations into the second half of 2025. • Revenues from collaborative research were $7.2 million for the year ended December 31, 2023. There was no revenue recognized for the same period in 2022. Revenue for the year ended December 31, 2023, consists of $4.4 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024038044/0000950170-24-038044-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$7.2 million"},{"label":"Net income","value":"$61.2 million"},{"label":"EPS","value":"$13.38 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}